MX2020006436A - Compuestos inhibidores del blanco mecanistico de rapamicina (mtor). - Google Patents
Compuestos inhibidores del blanco mecanistico de rapamicina (mtor).Info
- Publication number
- MX2020006436A MX2020006436A MX2020006436A MX2020006436A MX2020006436A MX 2020006436 A MX2020006436 A MX 2020006436A MX 2020006436 A MX2020006436 A MX 2020006436A MX 2020006436 A MX2020006436 A MX 2020006436A MX 2020006436 A MX2020006436 A MX 2020006436A
- Authority
- MX
- Mexico
- Prior art keywords
- mtor inhibitor
- inhibitor compounds
- compositions
- relates
- compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 229940124302 mTOR inhibitor Drugs 0.000 title abstract 4
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/20—Spiro-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La invención se relaciona con nuevos compuestos inhibidores de mTOR. Se caracteriza porque los compuestos inhibidores de mTOR son de la fórmula general (I). También se relaciona con composiciones que los comprenden, sus métodos de preparación y sus usos en composiciones como medicamento.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1771402A FR3075795A1 (fr) | 2017-12-21 | 2017-12-21 | Nouveaux composes inhibiteurs de mtor |
| PCT/EP2018/086074 WO2019122065A1 (fr) | 2017-12-21 | 2018-12-20 | Composes inhibiteurs de mtor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020006436A true MX2020006436A (es) | 2020-09-17 |
Family
ID=62017455
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020006436A MX2020006436A (es) | 2017-12-21 | 2018-12-20 | Compuestos inhibidores del blanco mecanistico de rapamicina (mtor). |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US11518767B2 (es) |
| EP (1) | EP3727390B1 (es) |
| JP (1) | JP2021506917A (es) |
| KR (1) | KR20200103032A (es) |
| CN (1) | CN111918654A (es) |
| AU (1) | AU2018392761B2 (es) |
| BR (1) | BR112020012201A2 (es) |
| CA (1) | CA3086243A1 (es) |
| CL (1) | CL2020001686A1 (es) |
| FR (1) | FR3075795A1 (es) |
| IL (1) | IL275531B2 (es) |
| MX (1) | MX2020006436A (es) |
| RU (1) | RU2020123899A (es) |
| SA (1) | SA520412289B1 (es) |
| SG (1) | SG11202005868XA (es) |
| WO (1) | WO2019122065A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110407703A (zh) * | 2019-08-02 | 2019-11-05 | 深圳振强生物技术有限公司 | 吲哚布芬杂质的制备方法 |
| EP4370517B1 (en) | 2021-07-12 | 2025-12-24 | Galderma Holding SA | Synthesis of chiral substituted pyrazolopyrimidine compounds |
| WO2023031738A1 (en) | 2021-08-31 | 2023-03-09 | Galderma Holding SA | Novel mtor inhibitor compounds |
| CN120058702A (zh) * | 2023-11-30 | 2025-05-30 | 武汉人福创新药物研发中心有限公司 | 含杂环的tead抑制剂 |
| WO2025185702A1 (en) * | 2024-03-06 | 2025-09-12 | Zai Lab (Shanghai) Co., Ltd. | Spirocyclic compounds as tead inhibitors |
| CN120774920A (zh) * | 2024-04-08 | 2025-10-14 | 浙江大学 | PI3Kδ-mTOR双靶点抑制剂及其制备方法和应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20060070572A (ko) | 2003-09-18 | 2006-06-23 | 콘포마 세러퓨틱스 코포레이션 | Ｈｓｐ90-저해제로서의 신규 헤테로시클릭 화합물 |
| EP2385053B1 (en) * | 2005-11-17 | 2013-10-02 | OSI Pharmaceuticals, Inc. | Intermediates for the preparation of fused bicyclic mTOR inhibitors |
| US20100331297A1 (en) | 2007-11-07 | 2010-12-30 | Foldrx Pharmaceuticals, Inc. | Modulation of protein trafficking |
| WO2009117482A1 (en) | 2008-03-19 | 2009-09-24 | Osi Pharmaceuticals, Inc | Mtor inhibitor salt forms |
| US9295673B2 (en) | 2011-02-23 | 2016-03-29 | Intellikine Llc | Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof |
| WO2012151562A1 (en) * | 2011-05-04 | 2012-11-08 | Intellikine, Llc | Combination pharmaceutical compositions and uses thereof |
| JP6122420B2 (ja) * | 2011-05-06 | 2017-04-26 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 多発性嚢胞疾患の治療 |
| BR112014008241A2 (pt) * | 2011-10-07 | 2017-04-18 | Cellzome Ltd | composto, composição farmacêutica, métodos para tratar, controlar, retardar ou prevenir doenças e distúrbios, e para preparar um composto, e, uso de um composto |
| CA2856803A1 (en) | 2011-11-23 | 2013-05-30 | Intellikine, Llc | Enhanced treatment regimens using mtor inhibitors |
| CA2833701A1 (en) * | 2013-11-19 | 2015-05-19 | Pharmascience Inc. | Protein kinase inhibitors |
| CN109071580B (zh) * | 2016-04-29 | 2022-05-24 | 默克专利有限公司 | 用于有机电致发光器件的材料 |
| FR3075794A1 (fr) | 2017-12-21 | 2019-06-28 | Galderma Research & Development | Nouveaux composes inhibiteurs de mtor |
-
2017
- 2017-12-21 FR FR1771402A patent/FR3075795A1/fr not_active Ceased
-
2018
- 2018-12-20 IL IL275531A patent/IL275531B2/en unknown
- 2018-12-20 SG SG11202005868XA patent/SG11202005868XA/en unknown
- 2018-12-20 CN CN201880090046.3A patent/CN111918654A/zh active Pending
- 2018-12-20 WO PCT/EP2018/086074 patent/WO2019122065A1/fr not_active Ceased
- 2018-12-20 KR KR1020207020410A patent/KR20200103032A/ko not_active Ceased
- 2018-12-20 MX MX2020006436A patent/MX2020006436A/es unknown
- 2018-12-20 JP JP2020534447A patent/JP2021506917A/ja not_active Ceased
- 2018-12-20 RU RU2020123899A patent/RU2020123899A/ru unknown
- 2018-12-20 EP EP18826025.1A patent/EP3727390B1/fr active Active
- 2018-12-20 AU AU2018392761A patent/AU2018392761B2/en not_active Expired - Fee Related
- 2018-12-20 CA CA3086243A patent/CA3086243A1/en active Pending
- 2018-12-20 BR BR112020012201-7A patent/BR112020012201A2/pt not_active IP Right Cessation
-
2020
- 2020-06-19 CL CL2020001686A patent/CL2020001686A1/es unknown
- 2020-06-19 US US16/907,122 patent/US11518767B2/en active Active
- 2020-06-21 SA SA520412289A patent/SA520412289B1/ar unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20200317683A1 (en) | 2020-10-08 |
| EP3727390B1 (fr) | 2023-03-22 |
| RU2020123899A3 (es) | 2022-02-17 |
| KR20200103032A (ko) | 2020-09-01 |
| IL275531B2 (en) | 2023-09-01 |
| CN111918654A (zh) | 2020-11-10 |
| IL275531A (en) | 2020-08-31 |
| EP3727390A1 (fr) | 2020-10-28 |
| WO2019122065A1 (fr) | 2019-06-27 |
| US11518767B2 (en) | 2022-12-06 |
| RU2020123899A (ru) | 2022-01-21 |
| AU2018392761B2 (en) | 2023-09-14 |
| AU2018392761A1 (en) | 2020-07-09 |
| FR3075795A1 (fr) | 2019-06-28 |
| SG11202005868XA (en) | 2020-07-29 |
| JP2021506917A (ja) | 2021-02-22 |
| CA3086243A1 (en) | 2019-06-27 |
| BR112020012201A2 (pt) | 2020-11-24 |
| CL2020001686A1 (es) | 2020-11-27 |
| SA520412289B1 (ar) | 2022-07-28 |
| IL275531B1 (en) | 2023-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12019550235A1 (en) | Kinase inhibitors and uses thereof | |
| NZ739676A (en) | Heteroaryl compounds as irak inhibitors and uses thereof | |
| MX2018010427A (es) | Formas solidas de un inhibidor de tienopirimidindiona acetil coa carboxilasa y metodos para su produccion. | |
| TN2018000276A1 (en) | Inhibitors of receptor-interacting protein kinase 1. | |
| MX2020006436A (es) | Compuestos inhibidores del blanco mecanistico de rapamicina (mtor). | |
| MX2020006434A (es) | Nuevos compuestos inhibidores del blanco mecanistico de rapamicina (mtor). | |
| GEP20186887B (en) | Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors | |
| PH12016500467B1 (en) | Aminoheteroarlyl benzamides as kinase inhibitors | |
| PH12018500408A1 (en) | Bicyclic compounds as atx inhibitors | |
| GEP201706725B (en) | Compounds and compositions as inhibitors of mek | |
| MX2016002794A (es) | Compuestos antiproliferativos. | |
| UA117032C2 (uk) | Селективний інгібітор фосфатидилінозитол-3-кінази-гамма | |
| PH12018500409A1 (en) | New bicyclic compounds as dual atx/ca inhibitors | |
| PH12017502051A1 (en) | TBK/IKKe INHIBITOR COMPOUNDS AND USES THEREOF | |
| SG10201908839QA (en) | 2,4-dihydroxy-nicotinamides as apj agonists | |
| MX2016016143A (es) | Compuestos de [1,2,4]triazol sustituido. | |
| PH12017501539A1 (en) | Disacetoxytubulysin h and analogs thereof | |
| GEP201606598B (en) | Heteroaromatic compounds as dopamine d1 ligands | |
| PH12016500347A1 (en) | Triazolopyridine compounds, compositions and methods of use thereof | |
| PH12017500737A1 (en) | Kcnq2-5 channel activator | |
| PH12017500459A1 (en) | Azetidinyloxyphenylpyrrolidine compounds | |
| MX2015016332A (es) | Inhibidores de alk biciclicos fusionados. | |
| MX2017008074A (es) | DERIVADOS DE IMIDAZOPIRIDAZINA COMO INHIBIDORES DE FOSFOINOSITIDA-3-QUINASAS BETA (PI3Kß). | |
| MX2016013439A (es) | Formas solidas de un compuesto farmaceuticamente activo. | |
| MX2017008076A (es) | DERIVADOS DE IMIDAZOPIRIDAZINA ENLAZADOS A HETEROCICLILO COMO INHIBIDORES DE PI3Kß. |